Currently Browsing: FDA Approved new Drugs

We have created the ultimate hangover cure in a pill (just in time for Christmas), claim U.S scientists

1. First remedy of its kind 2. Combination of aspirin and caffeine eradicates all symptoms in just 15 minutes 3. Designed by ex-financier with no pharmaceutical background 4. More effective than other products on the market Alcohol-induced hangovers will be a thing of the past thanks to a new over-the-counter remedy say U.S. scientists. A single dose of Blowfish can eradicate all symptoms sparked by a night of heavy drinking, such as nausea, vomiting and fatigue, in just 15 minutes. Hailed as a miracle cure by its maker, the pill – which contains 500 milligrams of aspirin, 60 milligrams of...
read more

Restless legs syndrome drug approved; questions linger

For those who believe their twitchy legs are an illness — there’s another pill for that. Restless legs syndrome — in which creeping and tugging sensations make moving your legs an irresistible urge — can now officially be treated with a seizure drug. The FDA approved gabapentin, or Horizant, on Thursday after two 12-week clinical trials showed it relieves the symptoms of restless legs syndrome, compared to a placebo. People with restless legs syndrome get the overwhelming urge to move their legs, especially after lying down. The condition is worst at night, and sufferers...
read more

FDA approves medical-image software for Apple mobile devices

The quality is deemed good enough for doctors to make diagnoses from MRIs and other medical images on an iPhone, iPad or iPod Touch. Reporting from Washington — Add diagnosing soft-tissue injuries to online banking, e-mail, video games and thousands of other applications available for the iPad, iPhone and iPod Touch. The Food and Drug Administration ushered in the era of mobile diagnostic radiology Friday, approving software for viewing images and making medical diagnoses from MRIs and CT, PET and SPECT scans on several of Apple Inc.’s popular hand-held devices. Read more…
read more

Gardasil vaccine OK to prevent anal cancer, FDA says

Approval expands use of HPV vaccine in young men and women ages 9 to 26 The Food and Drug Administration has agreed to expand the use of the popular HPV vaccine Gardasil to prevent anal cancer in young women and men, agency officials said Wednesday. The move approves the use of the vaccine in people ages 9 through 26 to prevent anal cancer and lesions caused by four types of the human papillomavirus — 6, 11, 16, and 18 — which are responsible for up to 90 percent of anal cancer cases. Gardasil, manufactured by Merck and Co. Inc., was originally approved to prevent cervical, vulvar and vaginal...
read more

FDA clears second clinical trial involving human embryonic stem cells

Another therapy derived from human embryonic stem cells is headed for clinical trials. Advanced Cell Technology Inc. said Monday that the Food and Drug Administration has cleared the way for its Phase I/II trial of retinal cells for patients with Stargardt’s macular dystrophy, a childhood version of macular degeneration. Get “Favorite Things” philosophy hope in a jar at Beauty.com! Up to 12 patients will be enrolled at several sites across the country, including the Casey Eye Institute in Portland, Ore., the University of Massachusetts Memorial Medical Center in Worcester, and UMDNJ...
read more

Cymbalta Approved for Chronic Joint and Muscle Pain

First approved as anti-depressant in 2004 FRIDAY, Nov. 5 (HealthDay News) — Cymbalta (duloxetine hydrochloride) has received expanded approval from the U.S. Food and Drug Administration to treat chronic musculoskeletal pain, stemming from conditions including lower back pain and osteoarthritis. Since its approval as an antidepressant in 2004, some 30 million people in the United States have used the drug, the agency said in a news release. The FDA also has sanctioned Cymbalta for the treatment of diabetic pain, generalized anxiety disorder and fibromyalgia. The most common side effects from...
read more

FDA Approves Once-Daily Lurasidone for Schizophrenia

October 29, 2010 — The US Food and Drug Administration (FDA) has approved the atypical antipsychotic lurasidone (Latuda tablets; Sunovion Pharmaceuticals Inc) for the once-daily treatment of patients with schizophrenia. Schizophrenia is a chronic, severe, and disabling brain disorder that affects about 2.4 million US adults. It is characterized by positive symptoms (eg, hallucinations, delusions, thought, and movement disorders), negative symptoms (eg, flat affect and lack of social interaction), and cognitive symptoms (such as poor executive functioning, attention span, and working memory). “Schizophrenia...
read more